The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Cell Line Development and Characterization Services by Sources of Cell Lines / Expression Systems (Mammalian, Microbial, Insect, Avian and Others), Applications of Cell Lines (Research and Development and Drug Development), and Geography (North America, Europe, Asia Pacific and Rest of the World): Industry Trends and Global Forecasts (2nd Edition), 2020-2030

  • Lowest Price Guaranteed From USD 5,499

  • Published
    January 2021

  • Pages
    483

  • View Count
    1695

Example Insights

Cell-Line-Development-and-Characterization-Services-Market-Context Cell-Line-Development-and-Characterization-Services-Market-Cell-based-R&D-Operations Cell-Line-Development-and-Characterization-Services-Market-Distribution-by-Gene-Delivery-Method Cell-Line-Development-and-Characterization-Services-Market-Geographical-Distribution
	Cell-Line-Development-and-Characterization-Services-Market-List-of-Cell-Line-Service-Providers Cell-Line-Development-and-Characterization-Services-Market-Types-of-Services-Offered Cell-Line-Development-and-Characterization-Services-Market-Competitive-Analysis Cell-Line-Development-and-Characterization-Services-Market-Partnerships-and-Collobarations
Cell-Line-Development-and-Characterization-Services-Market-Distribution-by-Company-Sizes Cell-Line-Development-and-Characterization-Services-Market-Market-Forcast    

 

Overview

Over the years, the biopharmaceutical market has grown into a promising, high value vertical within the overall pharmaceutical industry. In fact, nearly 29% and 25% of the total number of novel drugs approved by the Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) in 2018 and 2019, respectively, were biologics. As a result, the pipeline of biologics and biosimilars is growing at a commendable pace. Given that the development and manufacturing of such therapies require living biological systems, there has been a surge in demand for different types of cell lines. In fact, around 84% of the therapeutic proteins marketed in the last five years, were produced using various mammalian and microbial cells. A recent study revealed that over 30,000 research articles published in 33,000 journals featured data generated from experiments that used misidentified or contaminated cell lines. This is a genuine concern in the field of medical research, which is becoming increasingly dependent on cell-based assays and experimentation. Therefore, in modern medical research, proper cell line characterization is a necessity in order to preserve the authenticity and accuracy of experimental research.

Given the cost intensive nature of pharmacological R&D, medical researchers / drug developers are consistently on the lookout for ways to optimize operational efficiencies, as well as reduce affiliated costs; in this context, outsourcing has emerged as a preferred business model. Presently, there are several contact service providers that claim to have the necessary expertise to develop and characterize cell lines. The technical aspect of this field is also witnessing a lot of innovation, especially with regard to automating various steps of the cell line development process. New genome editing technologies, such as the CRISPR/Cas-9, are also being extensively used to improve the quality of recombinant cell lines. Unlike drug developers, the capabilities of service providers are usually more focused to their respective service portfolios. Moreover, such companies ensure that they have the latest upgrades in equipment and infrastructure, in order to improve the quality of services offered. In fact, in the recent past, a number of service providers offering cell lines-related services, have forged strategic alliances with and / or acquired other players, in order to further enhance their respective portfolios. Considering the growing trend of outsourcing and the ongoing efforts of service providers to improve / expand their offerings, we believe the contract services market for cell line development and characterization is likely to evolve at a steady pace, till 2030.

Scope of the Report

The “Cell Line Development and Characterization Services Market (2nd Edition), 2020-2030” report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution in this industry, over the next ten years. The study underlines an in-depth analysis of the services offered for the development and characterization of cell lines, which are intended for use in various R&D and / or therapeutic purposes. In addition to other elements, it includes:

  • A detailed review of the overall landscape of the cell line development services market, highlighting the contributions of contract service providers, along with the information on year of establishment, company size, location of headquarters, sources of cell lines and expression systems offered (mammalian, microbial, insect and avian), integrated cell line characterization, biosimilar cell line development and gene editing cell line development services offered, gene delivery method used (physical, chemical, biological and non-biological), type of gene expression (stable and transient), usage of serum-free / animal component free cell culture media, types of cell cultures (suspension and mixed growth properties), types of cells offered (recombinant, hybridoma and primary), applications of cell lines (R&D, biomanufacturing, diagnostics and cell therapy / regenerative medicine / tissue culture). In addition, the chapter includes information on additional cell line related services (bio-analytical / protein purification, cell banking, cell bank characterization, process development, GMP manufacturing and fill-finish), types of cell banks developed (master cell banks, working cell banks, research cell banks and end-of-production cell banks) and protein yield from cell lines. 
  • A company competitiveness analysis, highlighting prominent cell line development service providers based in different regions, taking into consideration their supplier strength (experience of the service provider), and portfolio specifications (sources of cell lines and expression systems handled, availability of proprietary / licensed technology platform, type of gene expression and availability of  additional cell line related services).
  • Elaborate profiles of cell line development service providers. Each company profile features a brief overview of the company, its financial information (if available), cell line development and complementary services portfolio and an informed future outlook. 
  • A detailed review of the overall landscape of the cell line characterization services market, highlighting the contributions of industry and non-industry players along with the information on year of establishment, company size, location of headquarters, types of cells handled (mammalian, microbial, insect and others), types of cell line characterization services offered (identity / stability testing, sterility / biosafety testing, expression testing and oncogenicity / tumorigenicity testing), types of cell line identity / stability testing services offered (analysis of cell morphology, cytochrome c oxidase 1 barcoding assay, DNA fingerprinting / profiling, gene copy number analysis, isozyme analysis, karyotype analysis, nucleic acid sequencing, southern blotting and viability testing) types of sterility / biosafety testing services offered (mycoplasma contamination testing, microbial contamination testing, viral / adventitious agents contamination testing, retroviral contamination testing and rodent virus testing / in-vivo biosafety testing), availability of other cell line related services (cell line development, cell banking and mycoplasma clearance service), information on regulatory accreditations / certifications and overall turnaround time. In addition, it lists the non-industry players and provides information on number of STR loci amplified, type of genotyping kit used and service fee charged. 
  • A company competitiveness analysis, highlighting prominent cell line characterization service providers based in different regions, taking into consideration their supplier strength (experience of the service provider), and portfolio specifications (sources of cell lines and expression systems handled and size of the service portfolio.)
  • Elaborate profiles of cell line characterization service providers. Each company profile features a brief overview of the company, its financial information (if available), cell line characterization services portfolio and an informed future outlook.
  • A detailed analysis of the partnerships that have been established in the cell line development and characterization domain since 2015, covering technology platform utilization agreements, R&D collaborations, licensing agreements, mergers and acquisitions, product development and / or commercialization agreements, process development agreements, clinical trial agreements, and other relevant deals.
  • Detailed profiles of the biorepositories across the globe that play an important role in developing cell lines and have also undertaken initiatives to limit the use of contaminated and / or misidentified cell lines. Each profile features a brief overview of the repository and its cell line characterization service portfolio. 
  • An elaborate discussion on the requirements established by various regulatory authorities, across different regions, related to characterization of cell lines. In addition, it provides insights from the various guideline documents that have been issued by these bodies on protocols that need to be followed and general tips for the testing of cell lines. It also features a brief historical overview and discussion on the contributions of key institutes / organizations involved in this domain.
  • A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing cell line development and / or cell line characterization services.

One of the key objectives of the report was to estimate the existing market size and future growth opportunities for cell line development and characterization service providers. Based on multiple parameters, such as the number of projects completed annually, price of the projects, the overall R&D expenditure available to CROs and the overall growth of the biologics market, we have developed informed estimates on the financial evolution of the market over the period 2020-2030. 

For cell line development services market, our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] sources of cell lines and expression systems (mammalian, microbial, insect and avian), [B] applications of cell lines (R&D operations and drug development), [C] company size (small, mid-sized and large) and key geographies (North America, Europe, Asia, Oceania and Rest of the World).

For cell line characterization services market, our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] sources of cell lines and expression systems (mammalian, microbial and others), [B] applications of cell lines (R&D operations and drug development), [C] type of service provider (industry players and non-industry players) and [D] key geographies (North America, Europe, Asia, Middle East & North Africa (MENA), Latin America (LATAM) and Rest of the World (RoW)).
To account for the uncertainties associated with this industry and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in this study were influenced by inputs solicited via a comprehensive survey and discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following industry stakeholders (in reverse chronological order):

  • Fai Poon (Founder and President, Quacell Biotechnology)
  • Louis Boon (Chief Scientific Officer, Polpharma Biologics)
  • Fan Chen (Former Vice President BioProcessing, LakePharma)
  • Michael Pointek (Founder and Managing Director, ARTES Biotechnology) 
  • Nienke Smits (Client Relations Manager, Immunoprecise Antibodies)
  • Oscar Hoogteijling (Former Global Business Development Manager, Polpharma Biologics)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading players offering cell line development services?
  • What kind of CDMO support is available for cell line development, across different regions?
  • What are the common sources, gene delivery methods, protein yield and affiliated services offered by the cell line development service providers?
  • Who are the leading industry and non-industry players offering cell line characterization services?
  • What are the most popular services offered for characterization of cell lines?
  • Which partnership models are commonly adopted by stakeholders in this industry?
  • How is the current and future opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to cell line development and characterization market?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. The summary offers a high-level view on the likely evolution of the cell line development and characterization services market in the mid to long term.

Chapter 3 provides a general introduction to cell cultures and cell lines, including details related to various types of cell lines, based on their sources of origin, and key characteristics, applications and concerns associated with their use in drug development and research. The chapter also elaborates the recombinant and hybridoma cell line development process workflow. Further, it outlines the general concepts of cell line characterization along with a detailed description of different types of testing methods used for such purposes. In addition, it also presents the advantages and associated risks related to outsourcing of cell line development and characterization operations. In this chapter, we have briefly discussed the most common services offered by the service providers, along with cell line development and characterization services.

Chapter 4 provides an overview of the overall cell line development services landscape. It includes information related to over 220 contract service providers that are currently active in this domain. It features an in-depth analyses of the market, information on year of establishment, company size, location of headquarters, sources of cell lines and expression systems offered (mammalian, microbial, insect and avian), integrated cell line characterization, biosimilar cell line development and gene editing cell line development services offered, gene delivery method used (physical, chemical, biological and non-biological), type of gene expression (stable and transient), usage of serum-free / animal component free cell culture media, types of cell cultures (suspension and mixed growth properties), types of cells offered (recombinant, hybridoma and primary), applications of cell lines (R&D, biomanufacturing, diagnostics and cell therapy / regenerative medicine / tissue culture). In addition, the chapter includes information on additional cell line related services (bio-analytical / protein purification, cell banking, cell bank characterization, process development, GMP manufacturing and fill-finish), types of cell banks developed (master cell banks, working cell banks, research cell banks and end-of-production cell banks) and protein yield from cell lines.

Chapter 5 provides an insightful competitiveness analysis of the cell line development service providers that we came across during our research. The analysis compares the companies on the basis of supplier strength (experience of the service provider) and service portfolio strength (considering sources of cell lines and expression systems offered, availability of proprietary / licensed technology platform, type of gene expression and availability of additional cell line related services).

Chapter 6 features detailed profiles of some of the key players that are active in the cell line development domain. Each profile presents a brief overview of the company, its cell line development and complementary services portfolio, financial information (if available), recent developments and an informed future outlook.

Chapter 7 provides an overview of the overall cell line characterization services landscape. It includes information related to over 140 industry and non-industry contract service providers that are currently active in this domain.  It features in-depth analyses of the market, based on a number of relevant parameters, such as year of establishment, company size, location of headquarters, types of cells handled (mammalian, microbial, insect and others), types of cell line characterization services offered (identity / stability testing, sterility / biosafety testing, expression testing and oncogenicity / tumorigenicity testing), types of cell line identity / stability testing services offered (analysis of cell morphology, cytochrome c oxidase 1 barcoding assay, DNA fingerprinting / profiling, gene copy number analysis, isozyme analysis, karyotype analysis, nucleic acid sequencing, southern blotting and viability testing) types of sterility / biosafety testing services offered (mycoplasma contamination testing, microbial contamination testing, viral / adventitious agents contamination testing, retroviral contamination testing and rodent virus testing / in-vivo biosafety testing), availability of other cell line related services (cell line development, cell banking and mycoplasma clearance service), information on regulatory accreditations / certifications and overall turnaround time. For non-industry players, the report features additional information on number of STR loci amplified, type of genotyping kit used and service fee charged. 

Chapter 8 provides an insightful competitiveness analysis of the cell line characterization service providers that we came across during our research. The analysis compares the companies on the basis of supplier strength (in terms of experience of the service provider) and service portfolio strength (considering sources of cell lines and expression systems handled and size of the service portfolio).

Chapter 9 features detailed profiles of some of the key players that are active in the cell line characterization domain. Each profile presents a brief overview of the company, its cell line characterization services portfolio, financial information (if available), recent developments and an informed future outlook.

Chapter 10 features an in-depth analysis and discussion on the various partnerships that have been inked between the players in the cell line development and characterization market in the time period between 2015 and 2020 (till September). It includes a brief description of partnership models (such as technology platform utilization agreements, R&D collaborations, licensing agreements, mergers and acquisitions, product development and / or commercialization agreements, process development agreements, clinical trial agreements and other relevant deals) adopted by the stakeholders.

Chapter 11 features detailed profiles of the biorepositories across the globe that play an important role in developing cell lines and have also undertaken initiatives to limit the use of contaminated and / or misidentified cell lines. Each profile features a brief overview of the repository and its cell line characterization service portfolio.

Chapter 12 presents an elaborate discussion on the requirements defined by various regulatory authorities, across different regions, related to the characterization of cell lines. In addition, it provides insights from the various guideline documents that have been issued by these bodies on protocols that need to be followed and general tips for the testing of cell lines. It also features a brief historical overview and discussion on the contributions of key institutes / organizations involved in this domain.

Chapter 13 presents a comprehensive market forecast analysis, highlighting the likely growth of cell line development services market till the year 2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of sources of cell lines / expression systems (mammalian, microbial, insect and avian), applications of cell lines (R&D operations and drug development), company size (small, mid-sized and large) and key geographical regions (North America, Europe, Asia, Oceania and Rest of the World).

Chapter 14 presents a comprehensive market forecast analysis, highlighting the likely growth of cell line characterization services market till the year 2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of sources of cell lines (mammalian, microbial and others), applications of cell lines (R&D operations and drug development), type of player (industry and non-industry) and key geographies (North America, Europe, Asia, Middle East & North Africa (MENA), Latin America (LATAM), Rest of the World (RoW)).  

Chapter 15 is a collection of interview transcripts of the discussions held with key stakeholders in the industry. We have presented details of interviews held with Fai Poon (Founder and President, Quacell Biotechnology), Louis Boon (Chief Scientific Officer, Polpharma Biologics), Fan Chen (Former Vice President BioProcessing, LakePharma), Michael Pointek (Founder and Managing Director, ARTES Biotechnology), Nienke Smits (Client Relations Manager, Immunoprecise Antibodies) and Oscar Hoogteijling (Former Global Business Development Manager, Polpharma Biologics).

Chapter 16 presents insights from the survey conducted for this study. The participants, who were primarily Directors / CXO level representatives, helped us develop a deeper understanding on the nature of their services and their associated commercial potential.

Chapter 17 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario.

Chapter 18 is an appendix, which provides tabulated data and numbers for all the figures in the report.

Chapter 19 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Key Questions Answered
1.3. Research Methodology
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Cell Culture
3.2.1. Types of Cell Cultures by Origin
3.2.1.1. Primary Cell Cultures
3.2.1.2. Secondary Cell Cultures
3.2.2. Types of Cell Cultures by Growth Properties
3.2.2.1. Adherent Cell Cultures
3.2.2.2. Suspension Cell Cultures

3.2.3. Classification by Types of Cell Lines
3.2.3.1. Finite Cell Lines
3.2.3.2. Continuous Cell Lines
3.2.3.3. Recombinant Cell Lines
3.2.3.4. Hybridoma Cell Lines

3.3.4. Classification by Sources of Cell Lines
3.3.4.1. Mammalian Cell Lines
3.3.4.2. Non-Mammalian Cell Lines

3.5. Overview of Cell Line Development
3.5.1. Recombinant Cell Line Development
3.5.1.1. Vector Construction
3.5.1.2. Transgene Delivery into Host Cells
3.5.1.3. Cell Line Selection and Gene Amplification
3.5.1.4. Clone Selection
3.5.1.5. Stability Studies

3.6.2. Hybridoma Cell Line Development

3.7. Overview of Cell Line Characterization
3.7.1. Identity Testing
3.7.1.1. Karyotype Analysis
3.7.1.2. Isozyme Analysis
3.7.1.3. Cytochrome C Oxidase 1 Barcoding Assay
3.7.1.4. Phenotype Analysis
3.7.1.5. DNA Fingerprinting
3.7.1.6. DNA Profiling

3.8.2. Genetic Stability Testing
3.8.3. Sterility / Biosafety Testing
3..3.1. Mycoplasma Contamination Testing
3.6.3.2. Viral Contamination Testing
3.6.3.3. Other Sterility Testing Methods

3.7. Additional Cell Line Related Services
3.7.1. Cell Banking
3.7.1.1. Classification of Cell Banks

3.7.2. Process Development
3.7.2.1. Upstream Process Development
3.7.2.2. Downstream Process Development

3.7.3. cGMP Manufacturing
 
3.8. Applications of Cell Lines
3.9. Factors Affecting the Quality of Cell Lines
3.10. Need for Outsourcing Cell Line Related Operations

4. CELL LINE DEVELOPMENT SERVICE PROVIDERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Cell Line Development Service Providers: List of Players
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Source of Cell Line and Expression System Offered
4.2.5. Analysis by Types of Services Offered
4.2.5.1. Integrated Cell Line Characterization
4.2.5.2. Biosimilar Cell Line Development
4.2.5.3. Genetically Modified Cell Line Development
4.2.6. Analysis by Gene Delivery Method Used
4.2.7. Analysis by Type of Gene Expression
4.2.8. Analysis by Availability of Serum-Free / Animal Component Free Culturing Capabilities
4.2.9. Analysis by Types of Cell Cultures
4.2.10. Analysis by Types of Cells
4.2.11. Analysis by Applications of Cell Lines
4.2.12. Analysis by Availability of Additional Cell Line Related Services
4.2.13. Analysis by Type of Cell Bank(s) Developed
4.2.14. Geographical Presence Analysis of Companies (offering multiple cell lines) by Sources of Cell Lines and Company Size
4.2.14.1. North America
4.2.14.2. Europe
4.2.14.3. Asia-Pacific
4.2.15. Geographical Presence Analysis of Companies (offering a single cell line) by Source of Cell Line and Company Size
4.2.16. Heat Map Analysis: Analysis by Year of Establishment, Location of Headquarters and Additional Cell Line Related Services
4.2.17. Heat Map Analysis: Distribution by Location of Headquarters and Combinations of Sources of Cell Lines Offered
4.2.18. Information on Protein Yield from Cell Lines

5. CELL LINE DEVELOPMENT SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Assumptions / Key Parameters
5.3.1. Company Competitiveness Analysis: Cell Line Development Service Providers in North America
5.3.2. Company Competitiveness Analysis: Cell Line Development Service Providers in Europe
5.3.3. Company Competitiveness Analysis: Cell Line Development Service Providers in Asia-Pacific
5.4. Summary

6. COMPANY PROFILES: CELL LINE DEVELOPMENT SERVICE PROVIDERS
6.1. Chapter Overview
6.2. Cell Line Development Service Providers: North America
6.2.1. Creative Biogene
6.2.1.1. Company Overview
6.2.1.2. Service Portfolio
6.2.1.3. Recent Developments and Future Outlook

6.2.2. Creative Biolabs
6.2.2.1. Company Overview
6.2.2.2. Service Portfolio
6.2.2.3. Recent Developments and Future Outlook

6.2.3. Hyprocell
6.2.3.1. Company Overview
6.2.3.2. Service Portfolio
6.2.3.3. Recent Developments and Future Outlook

6.2.4. LakePharma
6.2.4.1. Company Overview
6.2.4.2. Service Portfolio
6.2.4.3. Recent Developments and Future Outlook

6.2.5. Thermo Fisher Scientific
6.2.5.1. Company Overview
6.2.5.2. Financial Information
6.2.5.3. Service Portfolio
6.2.5.4. Recent Developments and Future Outlook

6.3. Cell Line Development Service Providers: Europe
6.3.1. FUJIFILM Diosynth Biotechnologies
6.3.1.1. Company Overview
6.3.1.2. Service Portfolio
6.3.1.3. Recent Developments and Future Outlook

6.3.2. Lonza
6.3.2.1. Company Overview
6.3.2.2. Financial Information
6.3.2.3. Service Portfolio
6.3.2.4. Recent Developments and Future Outlook

6.3.3. ProBioGen
6.3.3.1. Company Overview
6.3.3.2. Service Portfolio
6.3.3.3. Recent Developments and Future Outlook

6.3.4. Polpharma Biologics
6.3.4.1. Company Overview
6.3.4.2. Service Portfolio
6.3.4.3. Recent Developments and Future Outlook

6.3.5. Selexis
6.3.5.1. Company Overview
6.3.5.2. Service Portfolio
6.3.5.3. Recent Developments and Future Outlook

6.4. Cell Line Development Service Providers: Asia-Pacific
6.4.1. Detai Bio-Tech
6.4.1.1. Company Overview
6.4.1.2. Service Portfolio
6.4.1.3. Recent Developments and Future Outlook

6.4.2. WuXi Biologics
6.4.2.1. Company Overview
6.4.2.2. Financial Information
6.4.2.3. Service Portfolio
6.4.2.4. Recent Developments and Future Outlook

7. CELL LINE CHARACTERIZATION SERVICE PROVIDERS: MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Cell Line Characterization Service Providers: Overall Market Landscape
7.2.1. Cell Line Characterization Service Providers: Industry Players
7.2.1.1. Analysis by Year of Establishment
7.2.1.2. Analysis by Company Size
7.2.1.3. Analysis by Location of Headquarters
7.2.1.4. Analysis by Types of Cells Handled
7.2.1.5. Analysis by Type of Cell Line Characterization Service(s) Offered
7.2.1.6. Analysis by Type of Cell Line Identity / Stability Testing Service(s) Offered
7.2.1.7. Analysis by Type of Sterility / Biosafety Testing Service(s) Offered
7.2.1.8. Analysis by Availability of Additional Cell Line Related Services
7.2.1.9. Geographical Presence Analysis of Companies (offering multiple cell lines) by Location of Headquarters

7.2.2. Cell Line Characterization Service Providers: Non-Industry Players
7.2.2.1. Analysis by Service Location
7.2.2.2. Analysis by Types of Cells Handled
7.2.2.3. Analysis by Type of Cell Line Characterization Service(s) Offered
7.2.2.4. Analysis by Number of STR Loci Amplified
7.2.2.5. Analysis by Type of Genotyping Kit(s) Used

8. CELL LINE CHARACTERIZATION SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Methodology
8.3. Assumptions / Key Parameters
8.3.1. Company Competitiveness Analysis: Cell Line Characterization Service Providers in North America
8.3.2. Company Competitiveness Analysis: Cell Line Characterization Service Providers in Europe
8.3.3. Company Competitiveness Analysis: Cell Line Characterization Service Providers in Asia-Pacific
8.4. Summary

9. COMPANY PROFILES: CELL LINE CHARACTERIZATION SERVICE PROVIDERS
9.1. Chapter Overview
9.2. Cell Line Characterization Service Providers: North America
9.2.1. BioReliance
9.2.1.1. Company Overview
9.2.1.2. Service Portfolio
9.2.1.3. Recent Developments and Future Outlook

9.2.2. Charles River Laboratories
9.2.2.1. Company Overview
9.2.2.3. Financial Information
9.2.2.2. Service Portfolio 
9.2.2.3. Recent Developments and Future Outlook

9.2.3. Molecular Diagnostic Services
9.2.3.1. Company Overview
9.2.3.2. Service Portfolio
9.2.3.3. Recent Developments and Future Outlook

9.3. Cell Line Characterization Service Providers: Europe
9.3.1. Eurofins BioPharma Product Testing
9.3.1.1. Company Overview
9.3.1.2. Service Portfolio
9.3.1.3. Recent Developments and Future Outlook

9.3.2. Sartorius Stedim Biotech
9.3.2.1. Company Overview
9.3.2.2. Financial Information
9.3.2.3. Service Portfolio
9.3.2.4. Recent Developments and Future Outlook

9.3.3. SGS
9.3.3.1. Company Overview
9.3.3.2. Service Portfolio
9.3.3.3. Recent Developments and Future Outlook

9.4. Cell Line Characterization Service Providers: Asia-Pacific
9.4.1. LivoGen Pharmed
9.4.1.1. Company Overview
9.4.1.2. Service Portfolio
9.4.1.3. Recent Developments and Future Outlook

9.4.2. TFBS Bioscience
9.4.2.1. Company Overview
9.4.2.2. Service Portfolio
9.4.2.3. Recent Developments and Future Outlook

10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Cell Line Development and Characterization Service Providers: List of Partnerships and Collaborations
10.4. Analysis by Year of Partnership
10.5. Analysis by Type of Partnership
10.6. Analysis by Types of Cells Involved
10.7. Analysis by Type of Technology Platform Used
10.8. Analysis by Type of Indication
10.9. Analysis by Year of Partnership and Type of Partner
10.10. Analysis by Type of Partnership and Type of Partner
10.11. Most Active Players: Analysis by Number of Partnerships
10.12. Regional Analysis
10.13. Intercontinental and Intracontinental Agreements

11. CELL LINE REPOSITORIES
11.1. Chapter Overview
11.2. American Type Culture Collection (ATCC)
11.2.1. Overview
11.2.2. Service Portfolio

11.3. European Collection of Authenticated Cell Cultures (ECACC)
11.3.1. Overview
11.3.2. Service Portfolio

11.4. Leibniz Institute DSMZ
11.4.1. Overview
11.4.2. Service Portfolio

11.5. Coriell Institute for Medical Research
11.5.1. Overview
11.5.1.1. Service Portfolio

12. REGULATORY RECOMMENDATIONS AND GUIDELINES
12.1. Chapter Overview
12.2. History of Cell Line Authentication
12.3. Cell Line Authentication: Prominent Regulatory Authorities
12.3.1. Role of American Type Culture Collection (ATCC)
12.3.2. Role of International Cell Line Authentication Committee (ICLAC)
12.3.3. Role of Global Biological Standards Institute (GBSI)

12.4. Guidelines Issued by International Regulatory Agencies for Cell Line Characterization
12.4.1. World Health Organization (WHO)
12.4.2. The International Council for Harmonisation (ICH) of Technical Requirements for Pharmaceuticals for Human Use

12.5. Regulatory Guidelines for Cell Line Characterization in the US
12.6. Regulatory Guidelines for Cell Line Characterization in Europe
12.7. Regulatory Guidelines for Cell Line Characterization in Japan

13. CELL LINE DEVELOPMENT SERVICES: MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Overall Cell Line Development Services Market, 2020-2030
13.4. Cell Line Development Services Market, 2020-2030: Distribution by Sources of Cell Lines and Expression Systems Used
13.5. Cell Line Development Services Market, 2020-2030: Distribution by Applications
13.6. Cell Line Development Services Market, 2020-2030: Distribution by Company Size
13.7. Cell Line Development Services Market, 2020-2030: Distribution by Geography
13.7.1. Cell Line Development Services Market in North America, 2020-2030
13.7.1.1. Cell Line Development Services Market in North America, 2020-2030: Share of Small-sized Companies
13.7.1.2. Cell Line Development Services Market in North America, 2020-2030: Share of Mid-sized Companies
13.7.1.3. Cell Line Development Services Market in North America, 2020-2030: Share of Large Companies
13.7.1.4. Cell Line Development Services Market in North America, 2020-2030: Share of Research and Development Operations
13.7.1.5. Cell Line Development Services Market in North America, 2020-2030: Share of Drug Development Operations

13.7.2. Cell Line Development Services Market in Europe, 2020-2030
13.7.2.1. Cell Line Development Services Market in Europe, 2020-2030: Share of Small-sized Companies
13.7.2.2. Cell Line Development Services Market in Europe, 2020-2030: Share of Mid-sized Companies
13.7.2.3. Cell Line Development Services Market in Europe, 2020-2030: Share of Large Companies
13.7.2.4. Cell Line Development Services Market in Europe, 2020-2030: Share of Research and Development Operations
13.7.2.5. Cell Line Development Services Market in Europe, 2020-2030: Share of Drug Development Operations
13.7.2. Cell Line Development Services Market in Asia, 2020-2030
13.7.2.1. Cell Line Development Services Market in Asia, 2020-2030: Share of Small-sized Companies
13.7.2.2. Cell Line Development Services Market in Asia, 2020-2030: Share of Mid-sized Companies
13.7.2.3. Cell Line Development Services Market in Asia, 2020-2030: Share of Large Companies
13.7.2.4. Cell Line Development Services Market in Asia, 2020-2030: Share of Research and Development Operations
13.7.2.5. Cell Line Development Services Market in Asia, 2020-2030: Share of Drug Development Operations
13.7.3. Cell Line Development Services Market in Oceania, 2020-2030
13.7.3.1. Cell Line Development Services Market in Oceania, 2020-2030: Share of Small-sized Companies
13.7.3.2. Cell Line Development Services Market in Oceania, 2020-2030: Share of Mid-sized Companies
13.7.3.3. Cell Line Development Services Market in Oceania, 2020-2030: Share of Large Companies
13.7.3.4. Cell Line Development Services Market in Oceania, 2020-2030: Share of Research and Development Operations
13.7.3.5. Cell Line Development Services Market in Oceania, 2020-2030: Share of Drug Development Operations

13.7.4. Cell Line Development Services Market in Rest of the World, 2020-2030
13.7.4.1. Cell Line Development Services Market in Rest of the World, 2020-2030: Share of Small-sized Companies
13.7.4.2. Cell Line Development Services Market in Rest of the World, 2020-2030: Share of Mid-sized Companies
13.7.4.3. Cell Line Development Services Market in Rest of the World, 2020-2030: Share of Large Companies
13.7.4.4. Cell Line Development Services Market in Rest of the World, 2020-2030: Share of Research and Development Operations
13.7.4.5. Cell Line Development Services Market in Rest of the World, 2020-2030: Share of Drug Development Operations

14. CELL LINE CHARACTERIZATION SERVICES: MARKET SIZING AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Forecast Methodology and Key Assumptions
14.3. Overall Cell Line Characterization Services Market, 2020-2030
14.4. Cell Line Characterization Services Market, 2020-2030: Distribution by Sources of Cell Lines
14.5. Cell Line Characterization Services Market, 2020-2030: Distribution by Geography
14.6. Cell Line Characterization Services Market, 2020-2030: Distribution by Type of Industry
14.7. Cell Line Characterization Services Market, 2020-2030: Distribution by Stage of Development of Biologics

15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Northway Biotech
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Virgilijus Kupinas, Marketing and Business Development Coordinator (Q4 2020)

15.3. QuaCell Biotechnology
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Fai Poon, Founder and President (Q3 2020)

15.4. Polpharma Biologics
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Louis Boon, Chief Scientific Officer (Q3 2020)

15.5. LakePharma
15.5.1. Company Snapshot
15.5.2. Interview Transcript: Fan Chen, Former Vice President BioProcessing (Q3 2017)
15.6. ARTES Biotechnology
15.6.1. Company Snapshot
15.6.2. Interview Transcript: Michael Pointek, Founder and Managing Director (Q3 2017)

15.7. ImmunoPrecise Antibodies
15.7.1. Company Snapshot
15.7.2. Interview Transcript: Nienke Smits, Client Relations Manager (Q3 2017)

15.8. Bioceros (acquired by Polpharma Biologics)
15.8.1. Interview Transcript: Oscar Hoogteijling, Former Global Business Development Manager (Q3 2017)

16. SURVEY ANALYSIS
16.1. Chapter Overview
16.2. Overview of Respondents
16.3. Designation of Respondents
16.4. Survey Insights
16.4.1. Type of Cell Line Offered
16.4.2. Source of Cell Line
16.4.3. Applications of Cell Lines
16.4.4. Cell Line Characterization Services
16.4.5. Cell Banking Services
16.4.6. Biologics Manufacturing Services
16.4.7. Fill / Finish Services

17. CONCLUDING REMARKS
17.1. Chapter Overview
17.2. Key Takeaways

18. APPENDIX 1: TABULATED DATA

19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Primary and Secondary Cell Cultures
Figure 3.2 Initiation of Cell Cultures
Figure 3.3 Recombinant Cell Line Development: Process Workflow
Figure 3.4 Hybridoma Cell Line Development: Process Workflow
Figure 3.5 Sources of Non-Mammalian Cell Lines
Figure 3.6 Testing Methods for Cell Line Characterization
Figure 3.7 Karyotype Preparation: Process Workflow
Figure 3.8 DNA Hybridization: Process Workflow
Figure 3.9 DNA Fingerprinting: Process Workflow
Figure 3.10 DNA Fingerprinting: Process Workflow
Figure 3.11 Master and Working Cell Banks Production: Process Workflow
Figure 3.12 Cell Line Development in Overall Biomanufacturing Process
Figure 3.13 Applications of Cell Lines
Figure 3.14 Factors Affecting the Quality of Cell Lines
Figure 3.15 Advantages and Risks Associated with Outsourcing of Cell Line Related Operations
Figure 4.1 Cell Line Development Service Providers: Distribution by Year of Establishment
Figure 4.2 Cell Line Development Service Providers: Distribution by Company Size
Figure 4.3 Cell Line Development Service Providers: Distribution by Location of Headquarters
Figure 4.4 World Map Representation: Analysis by Geography
Figure 4.5 Cell Line Development Service Providers: Distribution by Sources of Cell Lines and Expression Systems Offered
Figure 4.6 Cell Line Development Service Providers Offering Multiple Cell Lines in North America: Distribution by Sources of Cell Lines and Company Size
Figure 4.7 Cell Line Development Service Providers Multiple Cell Lines in Europe: Distribution by Sources of Cell Lines and Company Size
Figure 4.8 Cell Line Development Service Providers Offering Multiple Cell Lines in Asia-Pacific: Distribution by Sources of Cell Lines and Company Size
Figure 4.9 Cell Line Development Service Providers Offering Single Cell Line: Distribution by Sources of Cell Lines and Company Size
Figure 4.10 Cell Line Development Service Providers: Distribution by Availability of Integrated Cell Line Characterization Service
Figure 4.11 Cell Line Development Service Providers: Distribution by Availability of Integrated Biosimilar Cell Line Development Service
Figure 4.12 Cell Line Development Service Providers: Distribution by Availability of Gene Editing Cell Line Development Service
Figure 4.13 Cell Line Development Service Providers: Distribution by Gene Delivery Methods Used
Figure 4.14 Cell Line Development Service Providers: Distribution by Type of Gene Expression
Figure 4.15 Cell Line Development Service Providers: Distribution by Usage of Serum-free / Animal Component Free Media
Figure 4.16 Cell Line Development Service Providers: Distribution by Types of Cell Cultures
Figure 4.17 Cell Line Development Service Providers: Distribution by Types of Cells Offered
Figure 4.18 Cell Line Development Service Providers: Distribution by Applications of Cell Lines
Figure 4.19 Cell Line Development Service Providers: Distribution by Types of Additional Cell Line Related Services Offered
Figure 4.20 Cell Line Development Service Providers: Distribution by Type of Cell Bank(s)
Figure 4.21 Heat Map Analysis: Analysis by Year of Establishment, Location of Headquarters and Cell Line Related Services
Figure 4.22 Heat Map Analysis: Distribution by Location of Headquarters and Sources of Cell Lines Offered
Figure 5.1 Company Competitiveness: Cell Line Development Service Providers in North America
Figure 5.2 Company Competitiveness: Cell Line Development Service Providers in Europe
Figure 5.3 Company Competitiveness: Cell Line Development Service Providers in Asia-Pacific
Figure 5.4 Company Competitiveness: Top Cell Line Development Service Providers
Figure 6.1 Thermo Fisher Scientific: Annual Revenues, FY 2015-H1 2020 (EUR Billion)
Figure 6.2 Lonza: Annual Revenues, FY 2015-H1 2020 (CHF Billion)
Figure 6.3 WuXi Biologics: Annual Revenues, FY 2016-H1 2020 (RMB Billion)
Figure 7.1 Cell Line Characterization Service Providers: Overall Market Landscape
Figure 7.2 Cell Line Characterization Service Providers (Industry Players): Distribution by Year of Establishment
Figure 7.3 Cell Line Characterization Service Providers (Industry Players): Distribution by Company Size
Figure 7.4 Cell Line Characterization Service Providers (Industry Players): Distribution by Location of Headquarters
Figure 7.5 World Map Representation: Analysis by Geography
Figure 7.6 Cell Line Characterization Service Providers (Industry Players): Distribution by Types of Cells Handled
Figure 7.7 Cell Line Development Service Providers (Industry Players): Distribution of Companies Offering Multiple Cell Lines by Location of Headquarters
Figure 7.8 Cell Line Development Service Providers (Industry Players): Distribution by Type of Cell Line Characterization Service(s) Offered
Figure 7.9 Cell Line Characterization Service Providers (Industry Players): Type of Cell Line Identity / Stability Testing Service(s) Offered
Figure 7.10 Cell Line Characterization Service Providers (Industry Players): Type of Cell Line Sterility / Biosafety Testing Service(s) Offered
Figure 7.11 Cell Line Characterization Service Providers (Industry Players): Distribution by Availability of Additional Cell Line Related Services
Figure 7.12 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Location of Organization
Figure 7.13 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Types of Cells Handled
Figure 7.14 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Type of Cell Line Characterization Service(s) Offered
Figure 7.15 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Type of Genotyping Kit(s) Used
Figure 7.16 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Number of STR Loci Amplified
Figure 8.1 Company Competitiveness: Cell Line Characterization Service Providers in North America
Figure 8.2 Company Competitiveness: Cell Line Characterization Service Providers in Europe
Figure 8.3 Company Competitiveness: Cell Line Characterization Service Providers in Asia-Pacific
Figure 8.4 Company Competitiveness: Top Cell Line Characterization Service Providers
Figure 9.1 Charles River Laboratories: Annual Revenues, FY 2015-Q1-Q3 2020 (USD Million)
Figure 9.2 Sartorius Stedim Biotech, Annual Revenues, FY 2016-H1 2020 (EUR Million)
Figure 9.3 SGS: Annual Revenues, FY 2015-H1 2020 (CHF Million)
Figure 10.1 Partnerships and Collaborations: Partnerships and Collaborations: Cumulative Trend by Year of Partnership, 2015-2020
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership (2015-2020)
Figure 10.4 Partnerships and Collaborations: Distribution by Type of Product being Licensed
Figure 10.5 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 10.6 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 10.7 Most Active Players: Distribution by Number of Partnerships
Figure 10.8 Partnerships and Collaborations: Regional Distribution
Figure 10.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 10.10 Most Popular Technology Platform: Distribution by Number of Partnerships
Figure 10.11 Partnerships and Collaborations: Distribution by Types of Cells Involved
Figure 10.12 Partnerships and Collaborations: Distribution by Type of Target Disease Indication
Figure 11.1 ATCC: Service Portfolio
Figure 11.2 ECACC: Biological Material Collection
Figure 11.3 ECACC: Service Portfolio
Figure 11.4 Leibniz Institute DSMZ: Biological Material Collection
Figure 11.5 Coriell Institute of Medical Research: Operating Segments
Figure 11.6 Coriell Institute for Medical Research: Service Portfolio
Figure 12.1 ICH Q5A (R1) Guidelines: Cell Bank Qualification
Figure 12.2 ICH Q5D Guidelines: Cell Bank Characterization
Figure 12.3 FDA Guidelines: Cell Bank Qualification
Figure 12.4 USP 63: Mycoplasma Detection in Cell Banks
Figure 12.5 CFR 610.18: Recommendations for Testing of Cell Lines
Figure 12.6 CFR 113.52: Recommendations for Testing of Cell Banks
Figure 12.7 EP 2.6.7: Recommendations for Mycoplasma Testing of Cell Banks
Figure 12.8 JP: Recommendations for Mycoplasma Testing of Cell Banks
Figure 13.1 Global Cell Line Development Services Market: 2020-2030 (USD Million)
Figure 13.2 Global Cell Line Development Services Market: Distribution by Sources of Cell Lines, 2020 and 2030 (USD Million)
Figure 13.3. Cell Line Development Services Market for Mammalian Cell Lines, 2020-2030 (USD Million)
Figure 13.4 Cell Line Development Services Market for Microbial Cell Lines, 2020-2030 (USD Million)
Figure 13.5 Cell Line Development Services Market for Insect Cell Lines, 2020-2030 (USD Million)
Figure 13.6 Cell Line Development Services Market for Avian Cell Lines, 2020-2030 (USD Million)
Figure 13.7 Global Cell Line Development Services Market: Distribution by Applications of Cell Lines, 2020 and 2030 (USD Million)
Figure 13.8 Cell Line Development Services Market for Bioproduction, 2020-2030 (USD Million)
Figure 13.9 Cell Line Development Services Market for Research and Development Operations, 2020-2030 (USD Million)
Figure 13.10 Global Cell Line Development Services Market: Distribution by Company Size, 2020 and 2030 (USD Million)
Figure 13.11 Cell Line Development Services Market for Small Companies, 2020-2030 (USD Million)
Figure 13.12 Cell Line Development Services Market for Mid-sized Companies, 2020-2030 (USD Million)
Figure 13.13 Cell Line Development Services Market for Large Companies, 2020-2030 (USD Million)
Figure 13.14 Global Cell Line Development Services Market: Distribution by Geography, 2020 and 2030 (USD Million)
Figure 13.15 Cell Line Development Services Market in North America, 2020-2030 (USD Million)
Figure 13.16 Cell Line Development Services Market in Europe, 2020-2030 (USD Million)
Figure 13.17 Cell Line Development Services Market in Asia, 2020-2030 (USD Million)
Figure 13.18 Cell Line Development Services Market in Oceania, 2020-2030 (USD Million)
Figure 13.19 Cell Line Development Services Market in the Rest of the World, 2020 (USD Million)
Figure 14.1 Global Cell Line Characterization Services Market, 2020-2030 (USD Million)
Figure 14.2 Global Cell Line Characterization Services Market: Distribution by Types of Projects, 2020-2030 (USD Million)
Figure 14.3 Global Cell Line Characterization Services Market: Distribution by Sources of Cell Lines, 2020 and 2030 (USD Million)
Figure 14.4 Cell Line Characterization Services Market for Mammalian Cell Lines, 2020-2030 (USD Million)
Figure 14.5 Cell Line Characterization Services Market for Microbial Cell Lines, 2020-2030 (USD Million)
Figure 14.6 Cell Line Characterization Services Market for Other Cell Lines, 2020-2030 (USD Million)
Figure 14.7 Global Cell Line Characterization Services Market: Distribution by Applications of Cell Lines, 2020 and 2030 (USD Million)
Figure 14.8 Cell Line Characterization Services Market for Bioproduction, 2020-2030 (USD Million)
Figure 14.9 Cell Line Characterization Services Market for Research and Development Operations, 2020-2030 (USD Million)
Figure 14.10 Global Cell Line Characterization Services Market: Distribution by Type of Service Provider, 2020 and 2030 (USD Million)
Figure 14.11 Cell Line Characterization Services Market for Industry Players, 2020-2030 (USD Million)
Figure 14.12 Cell Line Characterization Services Market for Non-Industry Players, 2020-2030 (USD Million)
Figure 14.13 Global Cell Line Characterization Services Market: Distribution by Geography, 2020 and 2030 (USD Million)
Figure 14.14 Cell Line Characterization Services Market in the US, 2020-2030 (USD Million)
Figure 14.15 Cell Line Characterization Services Market in Canada, 2020-2030 (USD Million)
Figure 14.16 Cell Line Characterization Services Market in the UK, 2020-2030 (USD Million)
Figure 14.17 Cell Line Characterization Services Market in France, 2020-2030 (USD Million)
Figure 14.18 Cell Line Characterization Services Market in Germany, 2020-2030 (USD Million)
Figure 14.19 Cell Line Characterization Services Market in Spain, 2020-2030 (USD Million)
Figure 14.20 Cell Line Characterization Services Market in Italy, 2020-2030 (USD Million)
Figure 14.21 Cell Line Characterization Services Market in Rest of Europe, 2020-2030 (USD Million)
Figure 14.22 Cell Line Characterization Services Market in China, 2020-2030 (USD Million)
Figure 14.23 Cell Line Characterization Services Market in Japan, 2020-2030 (USD Million)
Figure 14.24 Cell Line Characterization Services Market in India, 2020-2030 (USD Million)
Figure 14.25 Cell Line Characterization Services Market in Latin America, 2020-2030 (USD Million)
Figure 14.26 Cell Line Characterization Services Market in Middle East and North Africa, 2020-2030 (USD Million)
Figure 14.27 Cell Line Characterization Services Market in the Rest of the World, 2020-2030 (USD Million)
Figure 16.1 Survey Analysis: Distribution by Location of Organization
Figure 16.2 Survey Analysis: Distribution by Location of Manufacturing Facilities
Figure 16.3 Survey Analysis: Distribution by Seniority Level of Respondents
Figure 16.4 Survey Analysis: Distribution by Types of Cell Lines
Figure 16.5 Survey Analysis: Distribution by Sources of Cell Lines
Figure 16.6 Survey Analysis: Distribution by Applications of Cell Lines
Figure 16.7 Survey Analysis: Cell Line Characterization Services
Figure 16.8 Survey Analysis: Cell Banking Services
Figure 16.9 Survey Analysis: Biologics Manufacturing Services
Figure 16.10 Survey Analysis: Fill / Finish Services
Figure 17.1 Concluding Remarks: Current Market Landscape of Cell Line Development Services
Figure 17.2 Concluding Remarks: Current Market Landscape of Cell Line Characterization Services
Figure 17.3 Concluding Remarks: Geographical Distribution of Cell Line Development and Characterization Service Providers
Figure 17.4 Concluding Remarks: Partnerships and Collaborations
Figure 17.5 Concluding Remarks: Cell Line Development Services Market Sizing and Opportunity Analysis
Figure 17.6 Concluding Remarks: Cell Line Characterization Services Market Sizing and Opportunity Analysis

List Of Tables

Table 3.1 Comparison between Finite and Continuous Cell Lines
Table 3.2 Popular Mammalian Cell Lines used in Biopharmaceutical Production
Table 3.3 Human Cell Lines and Therapeutic Protein Products
Table 3.4 Cell Lines and Viral Vaccine Products
Table 4.1 Cell Line Development Service Providers: List of Players
Table 4.2 Cell Line Development Service Providers: Information on Sources of Cell Lines and Expresion Systems Offered
Table 4.3 Cell Line Development Service Providers: Information on Technology and Service related Parameters
Table 4.4 Cell Line Development Service Providers: Information on Cell Line Development Process Related Parameters
Table 4.5 Cell Line Development Service Providers: Information on Types of Cells Offered and Applications of Cell Lines
Table 4.6 Cell Line Development Service Providers: Information on Additional Cell Line Related Services
Table 4.7 Cell Line Development Service Providers: Information on Yield / Amount of Protein Expressed from Cell Lines
Table 6.1 Cell Line Development Service Providers: List of Profiled Companies
Table 6.2 Creative Biogene: Company Snapshot
Table 6.3 Creative Biogene: Overview of Cell Line Development Services
Table 6.4 Creative Biogene: Recent Developments and Future Outlook
Table 6.5 Creative Biolabs: Company Snapshot
Table 6.6 Creative Biolabs: Overview of Cell Line Development Services
Table 6.7 Creative Biolabs: Recent Developments and Future Outlook
Table 6.8 Hyprocell: Company Snapshot
Table 6.9 Hyprocell: Overview of Cell Line Development Services
Table 6.10 Hyprocell: Recent Developments and Future Outlook
Table 6.11 LakePharma: Company Snapshot
Table 6.12 LakePharma: Overview of Cell Line Development Services
Table 6.13 LakePharma: Recent Developments and Future Outlook
Table 6.14 Thermo Fisher Scientific: Company Snapshot
Table 6.15 Thermo Fisher Scientific: Overview of Cell Line Development Services
Table 6.16 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 6.17 FUJIFILM Diosynth Biotechnologies: Company Snapshot
Table 6.18 FUJIFILM Diosynth Biotechnologies: Overview of Cell Line Development Services
Table 6.19 FUJIFILM Diosynth Biotechnologies: Recent Developments and Future Outlook
Table 6.20 Lonza: Company Snapshot
Table 6.21 Lonza: Overview of Cell Line Development Services
Table 6.22 Lonza: Recent Developments and Future Outlook
Table 6.23 ProBioGen: Company Snapshot
Table 6.24 ProBioGen: Overview of Cell Line Development Services
Table 6.25 ProBioGen: Recent Developments and Future Outlook
Table 6.26 Polpharma Biologics: Company Snapshot
Table 6.27 Polpharma Biologics: Overview of Cell Line Development Services
Table 6.28 Polpharma Biologics: Recent Developments and Future Outlook
Table 6.29 Selexis: Company Snapshot
Table 6.30 Selexis: Overview of Cell Line Development Services
Table 6.31 Selexis: Recent Developments and Future Outlook
Table 6.32 Detai Bio-Tech: Company Snapshot
Table 6.33 Detai Bio-Tech: Overview of Cell Line Development Services
Table 6.34 Detai Bio-Tech: Recent Developments and Future Outlook
Table 6.35 WuXi Biologics: Company Snapshot
Table 6.36 WuXi Biologics: Overview of Cell Line Development Services
Table 6.37 WuXi Biologics: Recent Developments and Future Outlook
Table 7.1 Cell Line Characterization Service Providers: List of Industry Players
Table 7.2 Cell Line Characterization Service Providers (Industry Players): Information of Types of Cells Handled
Table 7.3 Cell Line Characterization Service Providers (Industry Players): Type of Cell Line Characterization Service(s) Offered
Table 7.4 Cell Line Characterization Service Providers (Industry Players): Type of Cell Identity / Stability Testing Service(s) Offered
Table 7.5 Cell Line Characterization Service Providers (Industry Players): Type of Cell Sterility / Biosafety Testing Service(s) Offered
Table 7.6 Cell Line Characterization Service Providers (Industry Players): Information on Additional Cell Line Related Services
Table 7.7 Cell Line Characterization Service Providers (Industry Players): Information on Regulatory Accreditations / Certifications and Overall Turnaround Time
Table 7.8 Cell Line Characterization Service Providers: List of Non-Industry Players and Types of Cells Handled
Table 7.9 Cell Line Characterization Service Providers (Non-Industry Players): Information on Type of Cell Line Characterization Service(s) Offered
Table 7.10 Line Characterization Service Providers (Non-Industry Players): Information on Genotyping Testing Services Offered
Table 7.11 Cell Line Characterization Service Providers (Non-Industry Players): Information on Service Fee Charged and Overall Turnaround Time
Table 7.12 Cell Line Characterization Service Providers: List of Players Offering Primary Cell / Stem Cell Characterization
Table 9.1 Cell Line Characterization Service Providers: List of Profiled Companies
Table 9.2 BioReliance: Company Snapshot
Table 9.3 BioReliance: Overview of Cell Line Development Services
Table 9.4 BioReliance: Recent Developments and Future Outlook
Table 9.5 Charles River Laboratories: Company Snapshot
Table 9.7 Charles River Laboratories: Overview of Cell Line Development Services
Table 9.8 Charles River Laboratories: Recent Developments and Future Outlook
Table 9.9 Molecular Diagnostic Services: Company Snapshot
Table 9.10 Molecular Diagnostic Services: Overview of Cell Line Development Services
Table 9.11 Molecular Diagnostic Services: Recent Developments and Future Outlook
Table 9.12 Eurofins BioPharma Product Testing: Company Snapshot
Table 9.13 Eurofins BioPharma Product Testing: Overview of Cell Line Development Services
Table 9.14 Eurofins BioPharma Product Testing: Recent Developments and Future Outlook
Table 9.15 Sartorius Stedim Biotech: Company Snapshot
Table 9.16 Sartorius Stedim Biotech: Financial Information
Table 9.17 Sartorius Stedim Biotech: Overview of Cell Line Development Services
Table 9.18 Sartorius Stedim Biotech: Recent Developments and Future Outlook
Table 9.19 SGS: Company Snapshot
Table 9.20 SGS: Overview of Cell Line Development Services
Table 9.21 SGS: Recent Developments and Future Outlook
Table 9.22 LivoGen Pharmed: Company Snapshot
Table 9.23 LivoGen Pharmed: Overview of Cell Line Development Services
Table 9.24 LivoGen Pharmed: Recent Developments and Future Outlook
Table 9.25 TFBS Bioscience: Company Snapshot
Table 9.26 TFBS Bioscience: Overview of Cell Line Development Services
Table 9.27 TFBS Bioscience: Recent Developments and Future Outlook
Table 10.1 Cell Line Development and Service Providers: List of Partnerships and Collaborations
Table 11.1 ATCC: Overview
Table 11.2 ECACC: Overview
Table 11.3 DSMZ: Overview
Table 12.1 WHO Recommendations: Cell Bank Characterization
Table 12.2 Regulatory Documents for Cell Line Characterization in the US
Table 12.3 USP 1050: Virus Testing in Cell Banks
Table 12.4 EP 5.2.3: Testing in Cell Banks
Table 15.1 Company Snapshot: Laragen
Table 15.2 Company Snapshot: QuaCell biotechnology
Table 15.3 Company Snapshot: Polpharma Biologics
Table 15.4 Company Snapshot: LakePharma
Table 15.5 Company Snapshot: ARTES Biotechnology
Table 15.6 Company Snapshot: ImmunoPrecise Antibodies
Table 16.1 Survey Analysis: Distribution by Location of Organization
Table 16.2 Survey Analysis: Distribution by Location of Manufacturing Facilities
Table 16.3 Survey Analysis: Distribution by Seniority Level of Respondents
Table 16.4 Survey Analysis: Distribution by Types of Cell Lines
Table 16.5 Survey Analysis: Distribution by Sources of Cell Lines
Table 16.6 Survey Analysis: Distribution by Applications of Cell Lines
Table 16.7 Survey Analysis: Cell Line Characterization Services
Table 16.8 Survey Analysis: Cell Banking Services
Table 16.9 Survey Analysis: Biologics Manufacturing Services
Table 16.10 Survey Analysis: Fill / Finish Services
Table 18.1 Cell Line Development Service Providers: Distribution by Year of Establishment
Table 18.2 Cell Line Development Service Providers: Distribution by Company Size
Table 18.3 Cell Line Development Service Providers: Distribution by Location of Headquarters
Table 18.4 Cell Line Development Service Providers: Distribution by Geography
Table 18.5 Cell Line Development Service Providers: Distribution by Sources of Cell Lines and Expression Systems Offered
Table 18.6 Cell Line Development Service Providers: Distribution by Availability of Integrated Cell Line Characterization Service
Table 18.7 Cell Line Development Service Providers: Distribution by Availability of Biosimilar Cell Line Development Service
Table 18.8 Cell Line Development Service Providers: Distribution by Availability of Gene Editing Cell Line Development Service
Table 18.9 Cell Line Development Service Providers: Distribution by Gene Delivery Methods Used
Table 18.10 Cell Line Development Service Providers: Distribution by Type of Gene Expression
Table 18.11 Cell Line Development Service Providers: Distribution by Availability of Serum-Free / Animal Component Free Culturing Capability
Table 18.12 Cell Line Development Service Providers: Distribution by Types of Cell Cultures
Table 18.13 Cell Line Development Service Providers: Distribution by Types of Cells Offered
Table 18.14 Cell Line Development Service Providers: Distribution by Applications of Cell Lines
Table 18.15 Cell Line Development Services Providers: Distribution by Types of Additional Cell Line Related Services Offered
Table 18.16 Cell Line Development Services Providers: Distribution by Type of Cell Bank(s) Developed
Table 18.17 Thermo Fisher Scientific: Annual Revenues, FY2015-H1 2020 (USD Billion)
Table 18.18 Lonza: Annual Revenues, FY 2015-H1 2020 (CHF Billion)
Table 18.19 WuXi Biologics: Annual Revenues, FY 2016-H1 2020 (RMB Billion)
Table 18.20 Cell Line Characterization Service Providers: Overall Market Landscape
Table 18.21 Cell Line Characterization Service Providers (Industry Players): Distribution by Year of Establishment
Table 18.22 Cell Line Characterization Service Providers (Industry Players): Distribution by Company Size
Table 18.23 Cell Line Characterization Service Providers (Industry Players): Distribution by Location of Headquarters
Table 18.24 Cell Line Characterization Service Providers: Distribution by Geography
Table 18.25 Cell Line Characterization Service Providers (Industry Players): Distribution by Types of Cells Handled
Table 18.26 Cell Line Development Service Providers (Industry Players): Analysis by Type of Cell Line Characterization Service(s) Offered
Table 18.27 Cell Line Characterization Service Providers (Industry Players): Type of Cell Line Identity / Stability Testing Service(s) Offered
Table 18.28 Cell Line Characterization Service Providers (Industry Players): Type of Cell Line Sterility / Biosafety Testing Service(s) Offered
Table 18.29 Cell Line Characterization Service Providers (Industry Players): Distribution by Availability of Additional Cell Line Related Services
Table 18.30 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Location of Organization
Table 18.31 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Types of Cells Handled
Table 18.32 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Type of Cell Line Characterization Service(s) Offered
Table 18.33 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Type of Genotyping Kit Used
Table 18.34 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Number of STR Loci Amplified
Table 18.35 Charles River Laboratories: Annual Revenues, 2015-Q3 2020 (USD Billion)
Table 18.36 Sartorius Stedim Biotech: Annual Revenues, 2015-Q3 2020 (EUR Billion)
Table 18.37 SGS: Annual Revenues, 2015-H1 2020 (CHF Billion)
Table 18.38 Partnerships and Collaborations: Cumulative Trend by Year of Partnership, 2015-2020
Table 18.39 Partnerships and Collaborations: Distribution by Type of Partnership
Table 18.40 Partnerships and Collaborations: Distribution by Year and Type of Partnership (2015-2020)
Table 18.41 Partnerships and Collaborations: Distribution by Type of Product being Licensed
Table 18.42 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 18.43 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 18.44 Most Active Players: Distribution by Number of Partnerships
Table 18.45 Partnerships and Collaborations: Regional Distribution
Table 18.46 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 18.47 Most Popular Technology Platforms: Distribution by Number of Partnerships
Table 18.48 Partnerships and Collaborations: Distribution by Types of Cells Involved
Table 18.49 Partnerships and Collaborations: Distribution by Type of Target Disease Indication
Table 18.50 Global Cell Line Development Services Market: 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.51 Global Cell Line Development Services Market: Distribution by Sources of Cell Lines, 2020 and 2030: Base Scenario (USD Million)
Table 18.52 Cell Line Development Services Market for Mammalian Cell Lines, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.53 Cell Line Development Services Market for Microbial Cell Lines, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.54 Cell Line Development Services Market for Insect Cell Lines, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.55 Cell Line Development Services Market for Avian Cell Lines, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.56 Global Cell Line Development Services Market: Distribution by Applications of Cell Lines, 2020 and 2030: Base Scenario (USD Million)
Table 18.57 Cell Line Development Services Market for Bioproduction, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.58 Cell Line Development Services Market for Research and Development Operations, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.59 Global Cell Line Development Services Market: Distribution by Company Size, 2020 and 2030: Base Scenario (USD Million)
Table 18.60 Cell Line Development Services Market for Small-sized Companies, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.61 Cell Line Development Services Market for Mid-sized Companies, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.62 Cell Line Development Services Market for Large Companies, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.63 Global Cell Line Development Services Market: Distribution by Geography, 2020 and 2030: Base Scenario (USD Million)
Table 18.64 Cell Line Development Services Market in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.65 Cell Line Development Services Market in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.66 Cell Line Development Services Market in Asia, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.67 Cell Line Development Services Market in Oceania, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.68 Cell Line Development Services Market in the Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.69 Global Cell Line Characterization Services Market, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.70 Global Cell Line Characterization Services Market: Distribution by Types of Projects, 2020-2030: Base Scenario (USD Million)
Table 18.71 Global Cell Line Characterization Services Market: Distribution by Sources of Cell Lines, 2020 and 2030: Base Scenario (USD Million)
Table 18.72 Cell Line Characterization Services Market for Mammalian Cell Lines, 2020-2030: Base and Optimistic Scenarios (USD Million)
Table 18.73 Cell Line Characterization Services Market for Microbial Cell Lines, 2020-2030: Base and Optimistic Scenarios (USD Million)
Table 18.74 Cell Line Characterization Services Market for Other Cell Lines, 2020-2030: Base and Optimistic Scenarios (USD Million)
Table 18.75 Global Cell Line Characterization Services Market: Distribution by Applications of Cell Lines, 2020 and 2030: Base Scenario (USD Million)
Table 18.76 Cell Line Characterization Services Market for Bioproduction, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.77 Cell Line Characterization Services Market for Research and Development Operations, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.78 Global Cell Line Characterization Services Market: Distribution by Type of Service Provider, 2020 and 2030: Base Scenario (USD Million)
Table 18.79 Cell Line Characterization Services Market for Industry Players, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.80 Cell Line Characterization Services Market for Non-Industry Players, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.81 Global Cell Line Characterization Services Market: Distribution by Geography, 2020 and 2030: Base Scenario (USD Million)
Table 18.82 Cell Line Characterization Services Market in the US, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.83 Cell Line Characterization Services Market in Canada, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.84 Cell Line Characterization Services Market in the UK, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.85 Cell Line Characterization Services Market in France, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.86 Cell Line Characterization Services Market in the Germany, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.87 Cell Line Characterization Services Market in Spain, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.88 Cell Line Characterization Services Market in Italy, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.89 Cell Line Characterization Services Market in Rest of Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.90 Cell Line Characterization Services Market in China, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.91 Cell Line Characterization Services Market in Japan, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.92 Cell Line Characterization Services Market in India, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.93 Cell Line Characterization Services Market in Latin America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.94 Cell Line Characterization Services Market in Middle East and North Africa, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.95 Cell Line Characterization Services Market in the Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.96 Survey Analysis: Distribution by Location of Organization
Table 18.97 Survey Analysis: Distribution by Location of Manufacturing Facilities
Table 18.98 Survey Analysis: Distribution by Seniority Level of Respondents
Table 18.99 Survey Analysis: Distribution by Type of Cell Lines
Table 18.100 Survey Analysis: Distribution by Source of Cell Lines
Table 18.101 Survey Analysis: Distribution by Applications of Cell Lines
Table 18.102 Survey Analysis: Cell Line Characterization Services
Table 18.103 Survey Analysis: Cell Banking Services
Table 18.104 Survey Analysis: Biologics Manufacturing Services
Table 18.105 Survey Analysis: Fill / Finish Services

List Of Companies

  1. 10x Genomics
  2. 3P Biopharmaceuticals
  3. 3SBio 
  4. A&G Pharmaceutical 
  5. Aarhus University Hospital 
  6. AbbVie
  7. Abcam
  8. ABclonal
  9. Abcuro
  10. Abdi Ibrahim Pharmaceuticals
  11. Abeomics
  12. ABGENEX
  13. ABL Bio
  14. Abnova
  15. AbSci
  16. Abzena
  17. AC Immune
  18. AcceGen
  19. Accelero Bioanalytics
  20. Accuprec Research Labs
  21. Accuratus Lab Services
  22. Accurus Biosciences
  23. ACE Biolabs
  24. ACROBiosystems
  25. Acticor Biotech
  26. ACYTE Biotech
  27. Adagene
  28. AdaptVac
  29. AddexBio Technologies
  30. Advanced Biomart
  31. Advaxis
  32. Affinita Biotech
  33. A-Frontier
  34. AGC Biologics
  35. Agenus
  36. Airway Therapeutics
  37. Akers Biosciences
  38. Akshaya Bio
  39. Albany Molecular Research (AMRI)
  40. Albert Ludwigs University of Freiburg
  41. Aldevron
  42. Alligator Bioscience
  43. Almirall
  44. Alpha Lifetech
  45. ALSTEM
  46. Altogen Labs
  47. Alvotech
  48. America Pharma Source
  49. Amicus Therapeutics
  50. Ampersand Capital Partners
  51. AMS Biotechnology (AMSBIO)
  52. Analytical Biological Services (ABS)
  53. Analytical Lab Group
  54. Applied Biological Materials (abm)
  55. Applied Genetics Laboratories (AGL)
  56. APRINOIA Therapeutics
  57. Aragen Bioscience
  58. Aravive
  59. ARETA International (ARETAINT)
  60. Artelo Biosciences
  61. ARTES Biotechnology
  62. AscentGene
  63. ASLAN Pharmaceuticals
  64. Astellas Pharma
  65. Asymchem
  66. AtaGenix Laboratories
  67. American Type Culture Collection (ATCC)
  68. ATGCell
  69. ATUM (formerly DNA2.0)
  70. ATZ Labs
  71. Augusta University
  72. Australian Genome Research Facility (AGRF)
  73. Austrianova
  74. AutekBio
  75. Avacta
  76. Avance Biosciences
  77. Avaxia Biologics
  78. Avid Bioservices (formerly Peregrine Pharmaceuticals)
  79. Axol Bioscience
  80. Axon Scientific
  81. Baliopharm
  82. BaseClear
  83. Batavia Biosciences
  84. Bavarian Nordic
  85. Bayer
  86. Beckman Coulter
  87. Beckman Research Institute of City of Hope
  88. BeiGene
  89. Berkeley Lights
  90. Bex CO
  91. Bhat Bio-tech India
  92. BIBITEC
  93. Bio Farma
  94. Bioasis Technologies
  95. BioAzure Technologies
  96. Bioceros
  97. BIO-ENGINEERING
  98. BioFactura
  99. Bioingenium
  100. Biointron Biological
  101. BioInvenu
  102. BioLife Solutions
  103. Biologics International
  104. BioMax Lab
  105. Bionique Testing Laboratories
  106. Bionova Scientific
  107. BioPharmaceuticals Australia (BPA)
  108. BioReliance
  109. Biosettia
  110. Biosphere
  111. BioSun Pharmed
  112. Bio-Synthesis (BSI)
  113. Biotechnology Hub Africa
  114. BioTek Instruments
  115. BioTickle
  116. Biovian
  117. BJ Bioscience
  118. BLIRT (Biolab Innovative Research Technologies)
  119. BMR Genomics
  120. Boehringer Ingelheim Animal Health
  121. Boehringer Ingelheim BioXcellence 
  122. Boston Institute of Biotechnology
  123. Boston Mountain Biotech
  124. BPS Bioscience
  125. BriaCell Therapeutics
  126. Brii Biosciences
  127. Bristol Myers Squibb
  128. Broad Institute of MIT and Harvard
  129. Brooks Automation
  130. Bruker
  131. Burnet Institute
  132. C&M Biolabs
  133. CALIXAR
  134. CANbridge Pharmaceuticals
  135. Canopy Biosciences
  136. Capital Biosciences
  137. Catalent Pharma Solutions
  138. Cell and Genome Engineering Core, University of California
  139. Cell Culture
  140. Cell Guidance Systems
  141. Cell Line Genetics
  142. Cellaria
  143. Cellca
  144. Cellero
  145. CellGenix
  146. CellKraft Biotech
  147. Cellomics Technology
  148. CellSafe
  149. Cells Online
  150. Celltheon
  151. Cellutron Life Technologies
  152. CELONIC Group (formerly Glycotope Biotechnology)
  153. Celplor
  154. Celther Polska
  155. Centre for Process Innovation (CPI)
  156. Cerbios-Pharma
  157. Ceva Santé Animale
  158. CEVEC Pharmaceuticals
  159. Changchun High & New Technology Industries Group
  160. Charles River Laboratories
  161. Children's Medical Research Institute
  162. ChinaPeptides
  163. Chiome Bioscience
  164. ChristianaCare's Helen F. Graham Cancer Center & Research Institute 
  165. Cipla Gulf
  166. Clean Cells
  167. Cleveland Clinic Lerner Research Institute
  168. Clongen Laboratories
  169. CLS Cell Lines Service
  170. CMAB Biopharma
  171. CMIC
  172. Cobra Biologics
  173. COBRE Grant Genomics, Biostatistics and Bioinformatics Core, Tulane    University
  174. Codex DNA (formerly SGI-DNA)
  175. Cognate BioServices 
  176. Complix
  177. Compugen
  178. CORE Diagnostics
  179. Cosmo Bio
  180. Cosmogenetech
  181. Covance
  182. CPE
  183. Creative Bioarray
  184. Creative Biogene
  185. Creative Biolabs
  186. Creative BioMart
  187. CSL
  188. Curaxys
  189. Cytovance Biologics
  190. Cytiva
  191. CZ Veterinaria
  192. DC Biosciences
  193. DC3 Therapeutics
  194. DefiniGEN
  195. Delphi Genetics
  196. Denali Therapeutics
  197. Detai Bio-Tech
  198. Diagnostic Cytogenetics (DCI)
  199. DiethelmKellerSiberHegner (DKSH)
  200. DNA Diagnostics Center
  201. DNA Forensics Laboratory
  202. DPx Holdings 
  203. Dr. KPC Life Sciences (formerly Chemgen Pharma)
  204. Duke University School of Medicine
  205. DYNAMIMED
  206. Early Drug Development Group (E2DG)
  207. Editas Medicine
  208. EirGenix
  209. Elabscience
  210. Element Materials Technology
  211. EMD Serono
  212. EMP Genetech
  213. Encure Biopharma
  214. EPICS Therapeutics
  215. EpiGex
  216. ERS Genomics
  217. Essen BioScience
  218. Eton Bioscience
  219. EuBiologics
  220. EUGENEX Biotechnologies
  221. EUPROTEIN
  222. Eurofins BioPharma Product Testing
  223. Eurofins DiscoverX
  224. Eurofins Discovery
  225. Eurofins Genomics
  226. Eurofins Scientific 
  227. Eurogentec
  228. EuroscreenFAST
  229. Eutilex
  230. Evotec
  231. Evox Therapeutics
  232. Excelimmune
  233. ExcellGene
  234. exonbio
  235. ExpreS2ion Biotechnologies
  236. ExpressCells
  237. Extherid Biosciences
  238. Fapon Biotech
  239. Faron Pharmaceuticals
  240. Feinberg School of Medicine, Northwestern University
  241. First BASE Laboratories
  242. FlashCell
  243. FlowMetric Life Sciences
  244. Fountain Biopharma
  245. Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB
  246. Fred Hutchinson Cancer Research Center
  247. French National Agency for Research on AIDS and Viral Hepatitis (ANRS) 
  248. Fuji Pharma
  249. FUJIFILM Diosynth Biotechnologies
  250. Fusion Antibodies
  251. G&P Biosciences
  252. G&W Biotechnologie 
  253. Gemini Biosciences
  254. Gene Center at Ludwig-Maximilians-Universität München
  255. Genea Biocells
  256. GeneBeyond
  257. GeneCopoeia
  258. Genedata
  259. Genenmed (formerly Cancercide)
  260. GENERI BIOTECH
  261. Generium
  262. Genetica DNA Laboratories 
  263. GENEWIZ
  264. Genexplore Diagnostics and Research Centre 
  265. GenomeScan
  266. Genovis
  267. genOway
  268. GenScript
  269. GenScript ProBio
  270. GenTarget
  271. GeoVax Labs
  272. German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)
  273. German Collection of Microorganisms and Cell Cultures
  274. GHO Capital Partners
  275. GI Innovation
  276. GlaxoSmithKline
  277. GlycoBac
  278. Glycotope
  279. Goodwin Biotechnology
  280. Pfizer- University of Granada- Junta de Andalucía Centre for Genomics and
  281. Oncological Research (GENYO)
  282. Grid Therapeutics
  283. Griffith University
  284. GT Biopharma
  285. GTP Technology
  286. GVK Biosciences (GVK BIO)
  287. handyem
  288. Haplogen Genomics
  289. Harbour BioMed
  290. Harvest Moon Pharmaceuticals
  291. Heidelberg Pharma
  292. Helsinki Institute of Life Science (HiLIFE)
  293. HemaCare
  294. Hepalink USA
  295. Hera BioLabs
  296. HistoCyte Laboratories
  297. Hoba Therapeutics
  298. Horizon Discovery
  299. Humanigen
  300. hylabs (Hy Laboratories)
  301. Hyprocell
  302. IBI - Istituto Biochimico Italiano Giovanni Lorenzini
  303. IDEXX Laboratories
  304. I-Mab Biopharma
  305. ImmuneOncia Therapeutics
  306. ImmuNext
  307. ImmunoGenesis
  308. ImmunoPrecise Antibodies
  309. IMMUNOSTEP
  310. Inhibrx
  311. InSCREENeX
  312. Institut für Forensische Genetik (IFG)
  313. Integrated BioTherapeutics
  314. IntelliCyt 
  315. International AIDS Vaccine Initiative (IAVI)
  316. Intervacc
  317. InVivo BioTech Services
  318. IRCCS San Martino Hospital – IST National Cancer Research Institute
  319. JAMP Pharma
  320. Janssen Biotech
  321. The Jenner Institute, University of Oxford
  322. JHL Biotech
  323. Johns Hopkins University
  324. JSR Life Sciences
  325. Shanghai Junshi Biosciences 
  326. Just Biotherapeutics
  327. KBIO Health (Osong Advanced Medical Industry Promotion Foundation) 
  328. KaryoLogic
  329. KBI Biopharma
  330. KEMP PROTEINS (formerly Kempbio)
  331. KMD Bioscience
  332. Korean Cell Line Bank
  333. Krishgen Biosystems
  334. KWR Water Research Institute
  335. KYinno
  336. Laboratorios Liomont
  337. Laboratory Corporation of America Holdings (LabCorp)
  338. LakePharma
  339. Laragen
  340. Laureate Biopharmaceutical Services
  341. Lava Therapeutics
  342. Legend Biotech
  343. Leiden University Medical Centre (LUMC)
  344. LFB Biomanufacturing
  345. Life Technologies (India)
  346. Limin International Group
  347. Lipum
  348. Livogen Pharmed
  349. Lonza
  350. Luminex
  351. Lumosa Therapeutics
  352. Mabion
  353. MabPlex International
  354. Mammoth Biosciences
  355. MassBiologics
  356. MaSTherCell Global
  357. University of Texas MD Anderson Cancer Center 
  358. Medvet Science
  359. MeiraGTx
  360. Memo Therapeutics
  361. Memorial Sloan Kettering Cancer Center (MSK)
  362. Merck
  363. Merus
  364. MGC Pharma (subsidiary of Mitsubishi Gas Chemical) 
  365. Michigan State University  
  366. Microbiology & Quality Associates
  367. Microbiology Research Associates
  368. Microsynth
  369. Midas Pharma
  370. MilliporeSigma (formerly Sigma-Aldrich)
  371. Minapharm Pharmaceuticals 
  372. Minerva Analytix
  373. Mithra Biotechnology
  374. MKS Instruments
  375. ModiQuest Research (acquired by ImmunoPrecise)
  376. Molecular Cloning Laboratories (MCLAB)
  377. Molecular Diagnostic Services
  378. Molecular Medicine (MolMed)
  379. Momenta Pharmaceuticals
  380. Moredun Scientific
  381. Mount Sinai Health System
  382. Multiplexion
  383. Multispan
  384. Mycenax Biotech
  385. Mycoplasma Experience
  386. Nashville Biosciences
  387. National Biologics Facility
  388. National Institute for Bioprocessing Research and Training (NIBRT)
  389. Naturalis Biodiversity Center
  390. Navrogen
  391. NewLink Genetics
  392. NGM Biopharmaceuticals
  393. Noachis Terra
  394. NorClone Biotech Laboratories
  395. Nordmark Biotech
  396. NorthGene
  397. Northway Biotechpharma
  398. Nouscom
  399. Novasep
  400. Novatein Biosciences
  401. Nucleome Informatics
  402. Oak BioSciences
  403. Octapharma
  404. Ogeda (formerly Euroscreen)
  405. Okmed Biotech
  406. Ology Bioservices (formerly Nanotherapeutics)
  407. Oncologie
  408. Oncotest
  409. OneWorld Biotech
  410. Oregon Health & Science University
  411. OSE Immunotherapeutics
  412. Oxford BioTherapeutics 
  413. Oxford Expression Technologies (OET)
  414. Oxford Genetics (OXGENE)
  415. Oxford Nanopore Technologies (ONT)
  416. PacificGMP
  417. Pall Biotech
  418. PanGen Biotech
  419. Paragon Bioservices
  420. Paraza Pharma
  421. PATH
  422. Patheon
  423. PathoQuest
  424. Pelican Therapeutics
  425. Penn Purchasing Services, University of Pennsylvania 
  426. Perfectus Biomed (formerly Extherid Biosciences)
  427. Phanes Therapeutics
  428. PharmAbcine
  429. Pharmaron
  430. PhaseBio Pharmaceuticals
  431. Phylex BioSciences
  432. Pieris Pharmaceuticals
  433. Pionyr Immunotherapeutics (formerly Precision Immune)
  434. Polpharma Biologics 
  435. Polymun Scientific
  436. Porton Biologics
  437. Precision Antibody
  438. Premas Biotech
  439. Prestige Biopharma
  440. Probiodrug
  441. ProBioGen
  442. Profacgen
  443. Progenics Pharmaceuticals
  444. Promega
  445. PROMISE Proteomics 
  446. Protein Technologies
  447. ProteinCT Biotech
  448. ProteoCell Biotechnologies
  449. ProteoGenix
  450. ProteoNic
  451. PX'Therapeutics (formerly Protein'eXpert)
  452. QED Bioscience
  453. qGenomics
  454. QIMR Berghofer Medical Research Institute
  455. QuaCell Biotechnology
  456. Queen’s University Belfast
  457. Rajiv Gandhi Centre for Biotechnology
  458. RD-Biotech
  459. ReliaTech (Receptor Ligand Technologies)
  460. Relief Therapeutics
  461. Rentschler Biopharma
  462. Richter-Helm BioLogics
  463. Roche
  464. Rockland Immunochemicals 
  465. Rodon Biologics
  466. Roswell Park Comprehensive Cancer Center
  467. Rubicon Genomics
  468. SAL Scientific
  469. Samsung Biologics
  470. Sandoz
  471. Sanford Burnham Prebys Medical Discovery Institute
  472. Sanofi
  473. Sanyou Biopharmaceuticals
  474. Sartorius Stedim BioOutsource
  475. Sartorius Stedim Biotech
  476. Sartorius Stedim Cellca
  477. SB Drug Discovery
  478. SecuGen 
  479. Selecxine
  480. Selexis
  481. Serum Institute of India
  482. SGS
  483. Shanghai Biowing Applied Biotechnology 
  484. Shanghai ChemPartner
  485. Shanghai Medicilon
  486. Shanghai Optima Biotechnology
  487. Molecular Diagnostics Laboratory of Dana - Farber Cancer Institute 
  488. Shenzhen Hepalink Pharmaceutical
  489. Shire
  490. Sigma-Aldrich
  491. Signosis
  492. Sinensis Life Sciences
  493. Sino Biological
  494. Six.02 Bioservices
  495. Solentim
  496. Sparta Systems
  497. SPEED Biosystems
  498. Sphere Fluidics
  499. Spicona
  500. STADA Arzneimittel
  501. Statens Serum Institut
  502. STC Biologics
  503. STCube
  504. Summit Pharmaceuticals International (SPI)
  505. Sundia MediTech
  506. Sunomix Biosciences
  507. Surface Oncology
  508. Svar Life Science (formerly Euro Diagnostica)
  509. Swedish Orphan Biovitrum
  510. SwissLumix
  511. Syd Labs
  512. Syngene International
  513. Synovel Sciences
  514. Synpromics 
  515. System Biosciences
  516. Takeda Pharmaceutical
  517. TCG Lifesciences
  518. tebu-bio
  519. Technion Israel Institute of Technology
  520. Teneobio
  521. TentaMedix (formerly MicroMol)
  522. Teva Pharmaceutical
  523. Texcell
  524. TFBS Bioscience
  525. The Beatson Institute for Cancer Research, University of Glasgow
  526. The Centre for Applied Genomics (TCAG)
  527. The European Collection of Authenticated Cell Cultures (ECACC)
  528. The Garvan Institute of Medical Research
  529. The Helmholtz Protein Sample Production Facility (PSPF)
  530. The Hospital for Sick Children (SickKids)
  531. The Human Protein Atlas
  532. The Microbial Type Culture Collection and Gene Bank (MTCC)
  533. The Native Antigen Company
  534. The Pirbright Institute
  535. The State University of New York at Albany
  536. The University of Manchester
  537. The University of Sheffield
  538. The University of Texas Medical Branch (UTMB)
  539. The University of Vermont (UVM)
  540. The Westmead Institute for Medical Research
  541. The Wistar Institute
  542. Therachon
  543. Therapure Biopharma 
  544. Thermo Fisher Scientific
  545. Tizona Therapeutics
  546. Toleranzia
  547. TPG Biologics
  548. Translational Research Platform for Veterinary Biologicals (TRPVB)
  549. Transposagen Biopharmaceuticals
  550. TransViragen
  551. Trend Pharma & Tech
  552. Trenzyme
  553. TrueBinding (formerly Immutics)
  554. Turgut Pharmaceuticals
  555. TWIN HELIX
  556. Twist Bioscience
  557. Twist Bioscience
  558. Ubiquigent
  559. UC Berkeley DNA Sequencing Facility, University of California
  560. UGA Biopharma
  561. UNC School of Medicine
  562. United BioLabs
  563. United Biomedical (UBI)
  564. United BioPharma (UBP)
  565. University of Arizona
  566. University of Cambridge
  567. University of Colorado Anschutz Medical Campus
  568. University of Connecticut
  569. University of Edinburgh
  570. University of Florida
  571. University of Illinois
  572. University of Maryland
  573. University of Missouri
  574. University of Pennsylvania
  575. University of Pittsburgh
  576. University of Sussex
  577. University of Technology, Sydney
  578. University of Utah 
  579. University of Warsaw
  580. University of Wisconsin School of Medicine and Public Health 
  581. U-Protein Express
  582. UT Southwestern Medical Center
  583. Vaccine Research Institute (VRI) 
  584. Vaccinex
  585. Vaccitech
  586. Valerius Biopharma
  587. Vall d'Hebron Research Institute
  588. Vectalys
  589. VectorBuilder
  590. Vectron Biosolutions
  591. VelaLabs
  592. Veterinary Medical Research & Development (VMRD)
  593. Vibalogics
  594. Vir Biotechnology
  595. Virongy
  596. ViruSure
  597. Vista Biologicals
  598. VTU Technology
  599. VxP Biologics
  600. Waisman Biomanufacturing
  601. Washington University in St. Louis
  602. WatsonBio Sciences
  603. Wayne State University
  604. Welgen
  605. Wuhan Dian Biotechnology
  606. WuXi Advanced Therapies
  607. WuXi AppTec
  608. WuXi Biologics
  609. Wyndham Forensic Group
  610. Xell
  611. Xencor
  612. Yale University
  613. Zellkraftwerk
  614. Zhejiang University 
  615. Zumutor Biologics
  616. Zymeworks
  617. ZyVersa Therapeutics 

PRICING DETAILS

USD 5,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com